The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2023 | How cutting-edge research is changing outcomes in myeloma and the need for novel endpoints in trials
Gareth Morgan, MD, PhD, FRCP, FRCPath, NYU Langone Health, New York City, NY, comments on how cutting-edge research is beginning to inform clinical practice and improve outcomes for patients with multiple myeloma (MM). Strategies incorporating novel agents are being investigated to increase the depth of response and inform management decisions, and quadruplet therapies are showing encouraging survival outcomes in patients. Prof. Morgan highlights a need to consider new endpoints in clinical trials to see the potential benefit of novel agents sooner and expedite their use in the upfront setting. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: Janssen Pharmaceuticals
